Connection

Raymond Anton to Middle Aged

Back to Details
This is a "connection" page, showing publications Raymond Anton has written about Middle Aged.
Raymond Anton
Connection Strength
1.565
Middle Aged
  1. Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial. Pharmacogenomics J. 2022 02; 22(1):1-8.
    View in: PubMed
    Score: 0.054
  2. Effects of Gabapentin on Dorsal Anterior Cingulate Cortex GABA and Glutamate Levels and Their Associations With Abstinence in Alcohol Use Disorder: A Randomized Clinical Trial. Am J Psychiatry. 2021 09 01; 178(9):829-837.
    View in: PubMed
    Score: 0.054
  3. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial. Alcohol Clin Exp Res. 2020 10; 44(10):2084-2096.
    View in: PubMed
    Score: 0.051
  4. Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial. JAMA Intern Med. 2020 05 01; 180(5):728-736.
    View in: PubMed
    Score: 0.050
  5. World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom. Addiction. 2020 09; 115(9):1668-1680.
    View in: PubMed
    Score: 0.049
  6. Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial. Alcohol Clin Exp Res. 2019 05; 43(5):979-987.
    View in: PubMed
    Score: 0.046
  7. Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder. Alcohol Clin Exp Res. 2018 12; 42(12):2453-2465.
    View in: PubMed
    Score: 0.045
  8. Nicotine-Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence. Alcohol Clin Exp Res. 2018 Apr; 42(4):751-760.
    View in: PubMed
    Score: 0.043
  9. Unique prefrontal GABA and glutamate disturbances in co-occurring bipolar disorder and alcohol dependence. Transl Psychiatry. 2017 07 04; 7(7):e1163.
    View in: PubMed
    Score: 0.041
  10. Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status. Neuropsychopharmacology. 2017 Dec; 42(13):2640-2653.
    View in: PubMed
    Score: 0.040
  11. Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels. Alcohol Clin Exp Res. 2017 01; 41(1):179-186.
    View in: PubMed
    Score: 0.039
  12. Relationship of Abnormal Chromatographic Pattern for Carbohydrate-Deficient Transferrin with Severe Liver Disease. Alcohol Alcohol. 2017 Jan; 52(1):24-28.
    View in: PubMed
    Score: 0.039
  13. Alcohol-Induced Stimulation Mediates the Effect of a GABRA2 SNP on Alcohol Self-Administrated among Alcohol-Dependent Individuals. Alcohol Alcohol. 2016 Sep; 51(5):549-54.
    View in: PubMed
    Score: 0.038
  14. Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol. Alcohol Alcohol. 2014 May-Jun; 49(3):261-70.
    View in: PubMed
    Score: 0.032
  15. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes. Alcohol Clin Exp Res. 2012 Nov; 36(11):2000-7.
    View in: PubMed
    Score: 0.029
  16. Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence. Alcohol Clin Exp Res. 2011 Nov; 35(11):2030-8.
    View in: PubMed
    Score: 0.027
  17. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry. 2011 Jul; 168(7):709-17.
    View in: PubMed
    Score: 0.026
  18. Liver disease and HPLC quantification of disialotransferrin for heavy alcohol use: a case series. Alcohol Clin Exp Res. 2010 Nov; 34(11):1956-60.
    View in: PubMed
    Score: 0.026
  19. Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms. J Clin Psychopharmacol. 2009 Aug; 29(4):334-42.
    View in: PubMed
    Score: 0.024
  20. A useful test for monitoring alcohol use. Behav Healthc. 2009 Jun; 29(6):38, 40.
    View in: PubMed
    Score: 0.023
  21. Blood pressure reduction during treatment for alcohol dependence: results from the Combining Medications and Behavioral Interventions for Alcoholism (COMBINE) study. Addiction. 2008 Oct; 103(10):1622-8.
    View in: PubMed
    Score: 0.022
  22. Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: do sex differences exist? Alcohol Clin Exp Res. 2008 May; 32(5):771-6.
    View in: PubMed
    Score: 0.021
  23. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol. 2008 Feb; 28(1):5-12.
    View in: PubMed
    Score: 0.021
  24. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb; 65(2):135-44.
    View in: PubMed
    Score: 0.021
  25. Alcohol consumption, %CDT, GGT and blood pressure change during alcohol treatment. Alcohol Alcohol. 2008 Mar-Apr; 43(2):192-7.
    View in: PubMed
    Score: 0.021
  26. What role does measuring medication compliance play in evaluating the efficacy of naltrexone? Alcohol Clin Exp Res. 2007 Apr; 31(4):596-603.
    View in: PubMed
    Score: 0.020
  27. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006 May 03; 295(17):2003-17.
    View in: PubMed
    Score: 0.019
  28. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol. 2005 Aug; 25(4):349-57.
    View in: PubMed
    Score: 0.018
  29. Effectiveness of naltrexone in a community treatment program. Alcohol Clin Exp Res. 2004 Nov; 28(11):1710-7.
    View in: PubMed
    Score: 0.017
  30. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol. 2004 Aug; 24(4):421-8.
    View in: PubMed
    Score: 0.017
  31. Self-report and biomarker alcohol screening by primary care physicians: the need to translate research into guidelines and practice. Alcohol Alcohol. 2004 Jul-Aug; 39(4):325-8.
    View in: PubMed
    Score: 0.017
  32. Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berl). 2004 Apr; 173(1-2):32-40.
    View in: PubMed
    Score: 0.016
  33. The World Health Organization Risk Drinking Levels Measure of Alcohol Consumption: Prevalence and Health Correlates in Nationally Representative Surveys of U.S. Adults, 2001-2002 and 2012-2013. Am J Psychiatry. 2021 06; 178(6):548-559.
    View in: PubMed
    Score: 0.013
  34. Multiple previous detoxifications are associated with less responsive treatment and heavier drinking during an index outpatient detoxification. Alcohol. 2000 Nov; 22(3):159-64.
    View in: PubMed
    Score: 0.013
  35. The Utility of Carbohydrate-Deficient Transferrin in Identifying Chronic Alcohol Users in the Injured Patient: Expanding the Toolkit. J Surg Res. 2021 01; 257:92-100.
    View in: PubMed
    Score: 0.013
  36. Reduction in World Health Organization Risk Drinking Levels and Cardiovascular Disease. Alcohol Clin Exp Res. 2020 08; 44(8):1625-1635.
    View in: PubMed
    Score: 0.013
  37. Drinking in alcoholics following an alcohol challenge research protocol. J Stud Alcohol. 2000 Mar; 61(2):220-4.
    View in: PubMed
    Score: 0.012
  38. Reduction in non-abstinent World Health Organization (WHO) drinking risk levels and drug use disorders: 3-year follow-up results in the US general population. Drug Alcohol Depend. 2019 08 01; 201:16-22.
    View in: PubMed
    Score: 0.012
  39. Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system. Int J Colorectal Dis. 2019 Jun; 34(6):1053-1059.
    View in: PubMed
    Score: 0.012
  40. Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials. JAMA Psychiatry. 2019 04 01; 76(4):374-381.
    View in: PubMed
    Score: 0.012
  41. Reduction in non-abstinent WHO drinking risk levels and depression/anxiety disorders: 3-year follow-up results in the US general population. Drug Alcohol Depend. 2019 04 01; 197:228-235.
    View in: PubMed
    Score: 0.011
  42. Contribution of carbohydrate deficient transferrin to gamma glutamyl transpeptidase in evaluating progress of patients in treatment for alcoholism. Alcohol Clin Exp Res. 1999 Jan; 23(1):115-20.
    View in: PubMed
    Score: 0.011
  43. Reduction in Nonabstinent WHO Drinking Risk Levels and Change in Risk for Liver Disease and Positive AUDIT-C Scores: Prospective 3-Year Follow-Up Results in the U.S. General Population. Alcohol Clin Exp Res. 2018 11; 42(11):2256-2265.
    View in: PubMed
    Score: 0.011
  44. The effect of drinking intensity and frequency on serum carbohydrate-deficient transferrin and gamma-glutamyl transferase levels in outpatient alcoholics. Alcohol Clin Exp Res. 1998 Oct; 22(7):1456-62.
    View in: PubMed
    Score: 0.011
  45. Female alcoholic outpatients and female college students: a correlational study of self-reported alcohol consumption and carbohydrate-deficient transferrin levels. J Stud Alcohol. 1998 Sep; 59(5):555-9.
    View in: PubMed
    Score: 0.011
  46. Transdiagnostic Effects of Ventromedial Prefrontal Cortex Transcranial Magnetic Stimulation on Cue Reactivity. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 07; 3(7):599-609.
    View in: PubMed
    Score: 0.011
  47. Childhood hyperactivity, gender, and Cloninger's personality dimensions in alcoholics. Addict Behav. 1997 Sep-Oct; 22(5):649-53.
    View in: PubMed
    Score: 0.010
  48. A double-blind comparison of abecarnil and diazepam in the treatment of uncomplicated alcohol withdrawal. Psychopharmacology (Berl). 1997 May; 131(2):123-9.
    View in: PubMed
    Score: 0.010
  49. Carbohydrate-deficient transferrin as an indicator of drinking status during a treatment outcome study. Alcohol Clin Exp Res. 1996 Aug; 20(5):841-6.
    View in: PubMed
    Score: 0.010
  50. Proof-of-Concept Study to Assess the Nociceptin Receptor Antagonist LY2940094 as a New Treatment for Alcohol Dependence. Alcohol Clin Exp Res. 2016 09; 40(9):1935-44.
    View in: PubMed
    Score: 0.010
  51. Association between a brief alcohol craving measure and drinking in the following week. Addiction. 2016 06; 111(6):1004-10.
    View in: PubMed
    Score: 0.009
  52. The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry. 1996 Mar; 53(3):225-31.
    View in: PubMed
    Score: 0.009
  53. Alcohol-related seizures and the kindling effect of repeated detoxifications: the influence of cocaine. Alcohol Alcohol. 1996 Mar; 31(2):135-43.
    View in: PubMed
    Score: 0.009
  54. The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res. 1995 Feb; 19(1):92-9.
    View in: PubMed
    Score: 0.009
  55. Methods to analyze treatment effects in the presence of missing data for a continuous heavy drinking outcome measure when participants drop out from treatment in alcohol clinical trials. Alcohol Clin Exp Res. 2014 Nov; 38(11):2826-34.
    View in: PubMed
    Score: 0.008
  56. Carbohydrate-deficient transferrin and gamma-glutamyltransferase as markers of heavy alcohol consumption: gender differences. Alcohol Clin Exp Res. 1994 Jun; 18(3):747-54.
    View in: PubMed
    Score: 0.008
  57. Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with chronic liver disease. Alcohol Clin Exp Res. 2014 Jun; 38(6):1706-11.
    View in: PubMed
    Score: 0.008
  58. Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals. Psychopharmacology (Berl). 2014 Sep; 231(18):3799-807.
    View in: PubMed
    Score: 0.008
  59. Two methods for measuring carbohydrate-deficient transferrin in inpatient alcoholics and healthy controls compared. Clin Chem. 1994 Mar; 40(3):364-8.
    View in: PubMed
    Score: 0.008
  60. A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence. Alcohol Clin Exp Res. 2014 Feb; 38(2):511-20.
    View in: PubMed
    Score: 0.008
  61. Response of psychotic depression subtypes to pharmacotherapy. J Affect Disord. 1993 Jun; 28(2):125-31.
    View in: PubMed
    Score: 0.008
  62. Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics. Psychopharmacology (Berl). 2013 Jun; 227(4):627-37.
    View in: PubMed
    Score: 0.008
  63. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol. 2013 Nov; 18(6):937-46.
    View in: PubMed
    Score: 0.007
  64. Hypermethylation of OPRM1 promoter region in European Americans with alcohol dependence. J Hum Genet. 2012 Oct; 57(10):670-5.
    View in: PubMed
    Score: 0.007
  65. Variation in regulator of G-protein signaling 17 gene (RGS17) is associated with multiple substance dependence diagnoses. Behav Brain Funct. 2012 May 16; 8:23.
    View in: PubMed
    Score: 0.007
  66. Linkage analysis followed by association show NRG1 associated with cannabis dependence in African Americans. Biol Psychiatry. 2012 Oct 15; 72(8):637-44.
    View in: PubMed
    Score: 0.007
  67. ACSL6 is associated with the number of cigarettes smoked and its expression is altered by chronic nicotine exposure. PLoS One. 2011; 6(12):e28790.
    View in: PubMed
    Score: 0.007
  68. Childhood adversity increases risk for nicotine dependence and interacts with a5 nicotinic acetylcholine receptor genotype specifically in males. Neuropsychopharmacology. 2012 Feb; 37(3):669-76.
    View in: PubMed
    Score: 0.007
  69. A CRHR1 haplotype moderates the effect of adverse childhood experiences on lifetime risk of major depressive episode in African-American women. Am J Med Genet B Neuropsychiatr Genet. 2011 Dec; 156B(8):960-8.
    View in: PubMed
    Score: 0.007
  70. GABRG1 and GABRA2 variation associated with alcohol dependence in African Americans. Alcohol Clin Exp Res. 2012 Apr; 36(4):588-93.
    View in: PubMed
    Score: 0.007
  71. No association between ADCYAP1R1 and post-traumatic stress disorder in two independent samples. Mol Psychiatry. 2012 Mar; 17(3):239-41.
    View in: PubMed
    Score: 0.007
  72. Increased severity of alcohol withdrawal in in-patient alcoholics with a co-existing anxiety diagnosis. Br J Addict. 1991 Jun; 86(6):719-25.
    View in: PubMed
    Score: 0.007
  73. Association of CHRNA4 polymorphisms with smoking behavior in two populations. Am J Med Genet B Neuropsychiatr Genet. 2011 Jun; 156B(4):421-9.
    View in: PubMed
    Score: 0.007
  74. Agitated depression in substance dependence. Drug Alcohol Depend. 2011 Jul 01; 116(1-3):163-9.
    View in: PubMed
    Score: 0.007
  75. Variation in the gene encoding the serotonin transporter is associated with a measure of sociopathy in alcoholics. Addict Biol. 2011 Jan; 16(1):124-32.
    View in: PubMed
    Score: 0.007
  76. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. Am J Psychiatry. 1990 Sep; 147(9):1203-8.
    View in: PubMed
    Score: 0.006
  77. Variation in nicotinic acetylcholine receptor genes is associated with multiple substance dependence phenotypes. Neuropsychopharmacology. 2010 Aug; 35(9):1921-31.
    View in: PubMed
    Score: 0.006
  78. Interaction of FKBP5 with childhood adversity on risk for post-traumatic stress disorder. Neuropsychopharmacology. 2010 Jul; 35(8):1684-92.
    View in: PubMed
    Score: 0.006
  79. Interactive effect of stressful life events and the serotonin transporter 5-HTTLPR genotype on posttraumatic stress disorder diagnosis in 2 independent populations. Arch Gen Psychiatry. 2009 Nov; 66(11):1201-9.
    View in: PubMed
    Score: 0.006
  80. Adverse childhood events as risk factors for substance dependence: partial mediation by mood and anxiety disorders. Addict Behav. 2010 Jan; 35(1):7-13.
    View in: PubMed
    Score: 0.006
  81. Association of markers in the 3' region of the GluR5 kainate receptor subunit gene to alcohol dependence. Alcohol Clin Exp Res. 2009 May; 33(5):925-30.
    View in: PubMed
    Score: 0.006
  82. Population admixture modulates risk for alcohol dependence. Hum Genet. 2009 Jun; 125(5-6):605-13.
    View in: PubMed
    Score: 0.006
  83. The thyroid axis and desipramine treatment in depression. Biol Psychiatry. 1989 Mar 15; 25(6):703-9.
    View in: PubMed
    Score: 0.006
  84. OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin Exp Res. 2009 Mar; 33(3):383-93.
    View in: PubMed
    Score: 0.006
  85. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med. 2008 Jun 09; 168(11):1188-99.
    View in: PubMed
    Score: 0.005
  86. Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes. J Stud Alcohol Drugs. 2008 Jan; 69(1):5-13.
    View in: PubMed
    Score: 0.005
  87. Variation in GABRA2 predicts drinking behavior in project MATCH subjects. Alcohol Clin Exp Res. 2007 Nov; 31(11):1780-7.
    View in: PubMed
    Score: 0.005
  88. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007 Oct 10; 298(14):1641-51.
    View in: PubMed
    Score: 0.005
  89. A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm. Alcohol Clin Exp Res. 2007 Feb; 31(2):221-7.
    View in: PubMed
    Score: 0.005
  90. Urinary free cortisol in psychotic depression. Biol Psychiatry. 1987 Jan; 22(1):24-34.
    View in: PubMed
    Score: 0.005
  91. The impact of alcohol dependence and posttraumatic stress disorder on cold pressor task response. J Stud Alcohol. 2006 Sep; 67(5):700-6.
    View in: PubMed
    Score: 0.005
  92. Case report of carbamazepine treatment of organic brain syndrome with psychotic features. J Clin Psychopharmacol. 1986 Aug; 6(4):232-4.
    View in: PubMed
    Score: 0.005
  93. Delusions of parasitosis: differential diagnosis and treatment. South Med J. 1985 Aug; 78(8):914-8.
    View in: PubMed
    Score: 0.004
  94. Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res. 2004 Sep; 28(9):1362-70.
    View in: PubMed
    Score: 0.004
  95. Differential brain activity in alcoholics and social drinkers to alcohol cues: relationship to craving. Neuropsychopharmacology. 2004 Feb; 29(2):393-402.
    View in: PubMed
    Score: 0.004
  96. Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial. J Clin Psychopharmacol. 2003 Dec; 23(6):553-62.
    View in: PubMed
    Score: 0.004
  97. Amoxapine elevates serum prolactin in depressed men. J Affect Disord. 1983 Nov; 5(4):305-10.
    View in: PubMed
    Score: 0.004
  98. Efficacy of amoxapine in psychotic depression. Am J Psychiatry. 1983 Oct; 140(10):1344-7.
    View in: PubMed
    Score: 0.004
  99. Alleles of a functional serotonin transporter promoter polymorphism are associated with major depression in alcoholics. Alcohol Clin Exp Res. 2003 Sep; 27(9):1402-8.
    View in: PubMed
    Score: 0.004
  100. A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacology. 2003 Apr; 28(4):755-64.
    View in: PubMed
    Score: 0.004
  101. Multiple family therapy and naltrexone in the treatment of opiate dependence. Drug Alcohol Depend. 1981 Sep; 8(2):157-68.
    View in: PubMed
    Score: 0.003
  102. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000 Nov-Dec; 35(6):587-93.
    View in: PubMed
    Score: 0.003
  103. A double-blind, placebo-controlled outpatient trial of pergolide for cocaine dependence. Drug Alcohol Depend. 2000 Aug 01; 60(2):161-8.
    View in: PubMed
    Score: 0.003
  104. Talk is cheap: measuring drinking outcomes in clinical trials. J Stud Alcohol. 2000 Jan; 61(1):55-63.
    View in: PubMed
    Score: 0.003
  105. Multiple previous alcohol detoxifications are associated with decreased medial temporal and paralimbic function in the postwithdrawal period. Alcohol Clin Exp Res. 1999 Jun; 23(6):1077-84.
    View in: PubMed
    Score: 0.003
  106. Carbohydrate-deficient transferrin and alcohol use in medical examiner cases. Alcohol. 1999 Jan; 17(1):7-11.
    View in: PubMed
    Score: 0.003
  107. Further validation of the Obsessive-Compulsive Drinking Scale (OCDS). Relationship to alcoholism severity. Am J Addict. 1998; 7(1):14-23.
    View in: PubMed
    Score: 0.003
  108. Ritanserin in the treatment of alcohol dependence--a multi-center clinical trial. Ritanserin Study Group. Psychopharmacology (Berl). 1996 Nov; 128(2):206-15.
    View in: PubMed
    Score: 0.002
  109. Cerebrospinal fluid concentrations of corticotropin-releasing hormone (CRH) and diazepam-binding inhibitor (DBI) during alcohol withdrawal and abstinence. Neuropsychopharmacology. 1996 Sep; 15(3):288-95.
    View in: PubMed
    Score: 0.002
  110. Carbohydrate-deficient transferrin levels in a female population. Alcohol Clin Exp Res. 1995 Feb; 19(1):100-3.
    View in: PubMed
    Score: 0.002
  111. Mood congruent and incongruent psychotic depressions: are they the same? J Affect Disord. 1994 Aug; 31(4):275-80.
    View in: PubMed
    Score: 0.002
  112. A correlational study of carbohydrate-deficient transferrin values and alcohol consumption among Hispanic college students. Alcohol Clin Exp Res. 1994 Jun; 18(3):653-6.
    View in: PubMed
    Score: 0.002
  113. A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res. 1992 Dec; 16(6):1007-13.
    View in: PubMed
    Score: 0.002
  114. Thyrotropin and prolactin response to thyrotropin-releasing hormone in depressed and nondepressed alcoholic men. Biol Psychiatry. 1990 Jan 01; 27(1):31-8.
    View in: PubMed
    Score: 0.002
  115. Direct comparison of urinary free cortisol excretion in patients with depression and panic disorder. Biol Psychiatry. 1989 Apr 01; 25(7):873-8.
    View in: PubMed
    Score: 0.001
  116. Alcohol detoxification and withdrawal seizures: clinical support for a kindling hypothesis. Biol Psychiatry. 1988 Mar 01; 23(5):507-14.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.